Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Disparate techologies meet in NeXagen-Vestar merger


Disparate technologies meet in NeXagen-Vestar merger

Mergers can take many shapes, combining companies with overlapping technologies or those with disparate technologies and skills. Last week's deal between NeXagen Inc. and Vestar Corp. is one of the latter, melding NXGN's expertise in oligonucleotide drug discovery with VSTR's liposome drug delivery technology and infrastructure in manufacturing, clinical trials and marketing.

By bringing together two companies

Read the full 646 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers